Drugs / IBI315
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04162327 | Nov 2019 → Jan 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05608785 | Jan → Dec 2023 | gastric cancer, gastroesophageal cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-29 | Hanmi Pharmaceutical Company Limited | Results 펜탐바디 적용 이중항체 항암신약 中國서 임상결과 첫 공개 hanmi.co.kr ↗
이 중 활성 용량 수준(≥1mg/kg)에서 치료 후 종양 평가를 최소 1회 이상 완료한 15명 환자 대상의 객관적 반응률(ORR)은 20%였으며 바이오 마커 분석을 통해 임상 반응을 보인 환자에서 말초 면역 세포의 더 높은 증식과 활성화가 나타난 것을 확인했다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-29 | Hanmi Pharmaceutical Company Limited | 펜탐바디 적용 이중항체 항암신약 中國서 임상결과 첫 공개 hanmi.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05608785 ↗ |
| Route | Intravenous | “intravenous drip” NCT05608785 ↗ |